A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Ia: To observe the safety and tolerability of BL-M11D1 in patients with relapsed/refractory
acute myeloid leukemia to determine the maximum tolerated dose (MTD) and dose-limiting
toxicity (DLT) of BL-M11D1. Ib: Further observe the safety and tolerability of BL-M11D1 at
the recommended dose in phase Ia to determine the recommended dose in phase II clinical study
(RP2D).